Therapeutic modalities to combat leishmaniasis, a review, Asian Pacific J Trop Dis, vol.6, pp.1-5, 2016. ,
New world and old world leishmania infections: a practical review, Dermatol Clin, vol.33, pp.579-593, 2015. ,
Leishmaniasis worldwide and global estimates of its incidence, PLoS One, vol.7, p.35671, 2012. ,
An update on pharmacotherapy for leishmaniasis, Expert Opin Pharmacother, vol.16, pp.1-16, 2014. ,
Selective effect of 2',6'-dihydroxy-4'-methoxychalcone isolated from Piper aduncum on Leishmania amazonensis, Antimicrob Agents Chemother, vol.43, pp.1234-1241, 1999. ,
Synthesis of chalcone analogues with increased antileishmanial activity, Bioorganic Med Chem, vol.14, pp.1538-1545, 2006. ,
Antileishmanial activity of licochalcone A in mice infected with Leishmania major and in hamsters infected with Leishmania donovani, Antimicrob Agents Chemother, vol.38, pp.1339-1344, 1994. ,
The antileishmanial activity of novel oxygenated chalcones and their mechanism of action, J Antimicrob Chemother, vol.43, pp.793-803, 1999. ,
Nanoemulsions containing a synthetic chalcone as an alternative for treating cutaneous leshmaniasis: optimization using a full factorial design, Int J Nanomedicine, vol.10, pp.5529-5542, 2015. ,
, Boletim informativo da redeLEISH, 2016.
Intralesional therapy of American cutaneous leishmaniasis with pentavalent antimony in Rio de Janeiro, Brazil -an area of Leishmania (V.) braziliensis transmission, Int J Dermatol, vol.36, pp.463-468, 1997. ,
Adverse effects of intralesional meglumine antimoniate and its influence on clinical laboratory parameters in the treatment of cutaneous leishmaniasis, Int J Dermatol, vol.51, pp.1221-1225, 2012. ,
Topical paromomycin with or without gentamicin for cutaneous leishmaniasis, N Engl J Med, vol.368, pp.524-532, 2013. ,
URL : https://hal.archives-ouvertes.fr/pasteur-00793585
Topical treatment for cutaneous leishmaniasis, Curr Opin Investig Drugs, vol.3, pp.538-544, 2002. ,
Drug permeation and barrier damage in Leishmania-infected mouse skin, J Antimicrob Chemother, vol.71, pp.1578-1585, 2016. ,
Biodegradable injectable in situ implants and microparticles for sustained release of montelukast: in vitro release, pharmacokinetics, and stability, AAPS PharmSciTech, vol.15, pp.772-780, 2014. ,
The uptake of PLGA micro or nanoparticles by macrophages provokes distinct in vitro inflammatory response, Int Immunopharmacol, vol.11, pp.1557-1563, 2011. ,
FDA's regulatory science program for generic PLA/PLGA -based drug products, Am Pharm Rev, vol.19, pp.5-9, 2016. ,
Depot subcutaneous injection with chalcone CH8-loaded poly(lactic-co-glycolic acid) microspheres as a single-dose treatment of cutaneous leishmaniasis, Antimicrob Agents Chemother, vol.62, pp.1822-1839, 2018. ,
S ?ntese e uso de chalconas para tratamento de doenc¸as parasit arias [Synthesis and use of chalcones for the treatment of parasitic diseases, 2004. ,
, Hansen solubility parameters: a user's handbook, 2007.
Properties of polymers: their correlation with chemical structure: their numerical estimation and prediction from additive group contributions, 2009. ,
Nano and microparticle engineering of water insoluble drugs using a novel spray-drying process, Colloids Surfaces B Biointerfaces, vol.90, pp.8-15, 2012. ,
Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity, Eur J Biochem, vol.267, pp.5421-5426, 2000. ,
Nitric oxide: a physiologic messenger molecule, Annu Rev Biochem, vol.63, pp.175-195, 1994. ,
Solubility and dissolution performances of spray-dried solid dispersion of Efavirenz in Soluplus, Drug Dev Ind Pharm, vol.9045, pp.1-13, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01619242
Effect of mixed solvents on polymer conformation -correlation between the hildebrand/hansen solubility parameters and the intrinsic viscosity of polymer solutions, Annu Trans Nord Rheol Soc, vol.21, pp.347-352, 2013. ,
Partial solubility parameters of poly(D,L-lactide-co-glycolide), Int J Pharm, vol.286, pp.19-26, 2004. ,
Solubility parameters as predictors of miscibility in solid dispersions, J Pharm Sci, vol.88, pp.1182-1190, 1999. ,
Evaluation of amorphous solid dispersion properties using thermal analysis techniques, Adv Drug Deliv Rev, vol.64, pp.396-421, 2012. ,
Theoretical and practical approaches for prediction of drug-polymer miscibility and solubility, Pharm Res, vol.23, pp.2417-2426, 2006. ,
Polyvinylpyrrolidone (PVP) -one of the most widely used excipients in pharmaceuticals: an Overview, Drug Deliv Technol, vol.8, pp.22-27, 2008. ,
Role of particle size in phagocytosis of polymeric microspheres, Pharm Res, vol.25, pp.1815-1821, 2008. ,
Nanoparticles for drug delivery: the need for precision in reporting particle size parameters, Eur J Pharm Biopharm, vol.69, pp.1-9, 2008. ,
, Fundamentals and applications of controlled release drug delivery, 2012.
Raman spectroscopy in pharmaceutical product design, Adv Drug Deliv Rev, vol.89, pp.3-20, 2015. ,
Design of PLGA-based depot delivery systems for biopharmaceuticals prepared by spray drying, Int J Pharm, vol.498, pp.82-95, 2015. ,
Type 1 interferon (IFNalpha/beta) and type 2 nitric oxide synthase regulate the innate immune response to a protozoan parasite, Immunity, vol.8, pp.77-87, 1998. ,
Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani, J Exp Med, vol.189, pp.741-746, 1999. ,
Expression of inducible nitric oxide synthase in skin lesions of patients with American cutaneous leishmaniasis, Infect Immun, vol.70, pp.4638-4642, 2002. ,
Synthesis, antioxidant evaluation, and quantitative structure-activity relationship studies of chalcones, Med Chem Res, vol.20, pp.482-492, 2011. ,
Novel anti-inflammatory chalcone derivatives inhibit the induction of nitric oxide synthase and cyclooxygenase-2 in mouse peritoneal macrophages, FEBS Lett, vol.453, pp.129-134, 1999. ,
Synthesis and inhibitory activity of dimethylamino-chalcone derivatives on the induction of nitric oxide synthase, Eur J Med Chem, vol.37, pp.699-705, 2002. ,